The new vaccine approach will help improve survival rates for ‘the next decades and more’, says Cancer Research UK’s chief clinician
The world’s first personalised mRNA cancer vaccine for melanoma halves the risk of patients dying or the disease returning, according to trial results that doctors described as “extremely impressive”.
Melanoma affects more than 150,000 people a year globally, according to 2020 figures from World Cancer Research Fund International.
More Stories
Amazon’s satellite launch designed to compete with Musk’s Starlink cancelled
As a geneticist, I will not mourn 23andMe and its jumble of useless health information | Adam Rutherford
Tesla stops taking orders in China for two models imported from US